DOCSLIB.ORG

February 11-12, 2013 the Waldorf Astoria New York

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
February 11-12, 2013 the Waldorf Astoria New York February 11-12, 2013 The Waldorf Astoria New York 15th ANNU AL EVENT Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event. 7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss. -2- Advisory Committee Tom Brakel, MD Portfolio Manager, Federated Kaufmann Funds John Chambers Managing Director & Head of Healthcare Investment Banking, Roth Capital Partners Michael Gilman, PhD Senior Vice President Early-Stage Programs, Biogen Idec Michael Hay Vice President, BioMedTracker Product Manager, Sagient Research Systems Peter Kolchinksky, PhD Managing Partner, RA Capital Management, LLC Arlene Morris CEO, Syndax Pharmaceuticals Oleg Nodelman Founder & Managing Director, EcoR1 Capital David Sable, MD Portfolio Manager, Special Situations Fund Joel Sendek Managing Director, Head Healthcare Equity Research, Stifel Nicolaus Nathan Tinker, PhD Executive Director New York Biotechnology Association -3- Fireside Chats Fireside chats feature candid discussions between biopharma executives and Wall Street analysts. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. Jean-Jacques Bienaimé Chief Executive Officer BioMarin Pharmaceutical Inc. N. Anthony Coles Chairman & CEO Onyx Pharmaceuticals, Inc. Robert Hugin Chairman and Chief Executive Officer Celgene Corporation John C. Lechleiter, PhD Chairman, President and CEO Eli Lilly and Company John F. Milligan, PhD President and Chief Operating Officer, Gilead Sciences, Inc. -4- Plenary Sessions Word on the Street: The Buy-Side View for 2013 Monday, February 11th, 12:00pm – 12:55pm Portfolio managers and senior buy-side analysts forecast the year ahead in biotech. This lively panel discussion will be primed with the results of this year’s Investor Perception Study, conducted by BIO’s Industry Analysis Team and ISI Group. Panelists will field a range of questions from valuations and volatility to challenges and opportunities facing institutional investors today. Moderator: • Mark Schoenebaum, MD, Senior Managing Director and Head, Healthcare Research, ISI Group Panelists: • Samuel D. Isaly, Managing Partner, OrbiMed Advisors • Oleg Nodelman, Founder & Managing Director, EcoR1 Capital • Nathan Sadeghi-Nejad, Partner, Palkon Capital Management Tales From the Wild West (Wing): Reflections from White House Chiefs of Staff Tuesday, February 12th, 4:00pm – 4:55pm The election chips have fallen and the country is gearing up for another four years of economic challenges and political wrangling. With divided government, compromises will be difficult and time consuming to reach, but will be necessary to deal with big issues the U.S. faces. Although the fiscal cliff has been averted for now, an unsteady economy and concerns over U.S. debt remain. This session will feature two former White House Chiefs of Staff who have served in the trenches under President Bill Clinton and President George W. Bush. BIO’s CEO and former Congressman, James C. Greenwood, will lead an in depth and lively discussion between Joshua Bolten and John Podesta, who will proffer their views of the political landscape, the outlook for the next four years, the outcome of these key issues and more. Moderator: • James C. Greenwood, President & CEO, BIO Panelists: • Joshua Bolten, 22nd White House Chief of Staff and Managing Director, Rock Creek Global Advisors • John Podesta, Former White House Chief of Staff and Founder and Chair, Center for American Progress Mark Schoenebaum Samuel D. Isaly Oleg Nodelman Nathan James C. Greenwood Joshua Bolten John Podesta Sadeghi-Nejad -5- Therapeutic Workshops Oncology: Panning for Gold—Prospecting the Pancreatic Pipeline Monday, February 11th, 10:30am - 11:25am Though pancreatic cancer is the 4th leading cancer malignancy, resulting in nearly 37,000 deaths a year in the US, the pipeline has garnered less attention from industry and the investment community than other oncology indications. There are only two currently approved single agent therapies for this serious disease, but combination treatment regimens are showing tremendous promise yielding a significant increase in overall survival rates. With several phase II and III trials now in the works and positive readouts expected in 2013, the industry is becoming much more intrigued by this potentially underserved space. Hear clinical experts entrenched in the pancreatic cancer late stage treatment pipeline proffer their insights on the future of the disease. Moderator: • Brian Klein, MD, Vice President & Senior Biotechnology Analyst, Stifel, Nicolaus & Company Panelists: • John Chabot, MD, FACS, Chief, Division of GI/Endocrine Surgery and Executive Director, Pancreas Center, New York Presbyterian Hospital/Columbia University • Stewart M. Kroll, Senior Vice President, Clinical Operations and Biostatistics, Threshold Pharmaceuticals • Peter Laivins, Vice President, Late Stage Drug Development, Merrimack Pharmaceuticals • Kenneth H. Yu, MD, Assistant Professor, Memorial Sloan-Kettering Cancer Center -6- Orphan Drugs: Making Rare Diseases Rarer Tuesday, February 12th, 9:00am - 9:55am The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering innovation for rare diseases. With a record 460 medicines in late-stage clinical trials, biopharmaceutical companies have embraced rare disease medicine and are rapidly developing the pipeline with hopes of achieving the ever elusive blockbuster drug. Some companies have even taken a step beyond and focused primarily on ultra rare disease, potentially providing an even more compelling opportunity. This panel will provide an in-depth analysis of the thriving market opportunity that is rare disease by featuring industry, clinical and regulatory experts specializing in this exciting field. Moderator: • Ritu S. Baral, Principal, Sr. Analyst- Biotechnology Equity Research, Genuity Partners Panelists: • Marc Beer, Chief Executive Officer, Aegerion Pharmaceuticals • John F. Crowley, Chairman & CEO, Amicus Therapeutics • Pamela Gavin, Senior Vice President, National Organization for Rare Disorders (NORD) • Hans GCP Schikan, PharmD, Chief Executive Officer, Prosensa • Alvin V. Shih, MD, Chief Operating Officer, Pfizer Rare Disease Research Unit Oncology: The CLL Chronicles—The Next Chapter in Clinical Developments Tuesday, February 12th, 12:00pm - 12:55pm Moderator: • Joel Sendek, Managing Director & Biotechnology Analyst, Stifel Nicolaus & Company Panelists: • Jacqueline Barrientos, MD, Assistant Professor of Medicine, Hofstra North Shore-LIJ School of Medicine CLL Research and Treatment Program • John F. Gerecitano, MD, PhD, Medical Oncologist & Hematologist, Memorial Sloan-Kettering Cancer Center • Kanti Rai, MD, Joel Finkelstein Cancer Foundation Professor of Medicine and Professor of Molecular Medicine, Hofstra North Shore-LIJ School of Medicine -7- Business Roundtables Show Me the Money: Reimbursement in an ACA World Monday, February 11, 9:00am - 9:55am With many key provisions of the Affordable Care Act (ACA) slated to take effect in 2013 and beyond, the industry is facing sweeping changes to the managed care and reimbursement road map. Additionally, nearly 30 million more Americans will now have access to health insurance. How will this new environment affect relationships between patients, payors, providers and biopharma companies? How could changes to federal health plans and the creation of state-run insurance exchanges alter biopharma company strategy, from business development to R&D activities? This reimbursement roundtable will feature payors, providers, and other stakeholders from across the industry discussing ACA implementation and the wider reimbursement landscape. Moderator: • Roger Longman, Chief Executive Officer, Real Endpoints Panelists: • Peter Bach, MD, MAPP, Director, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center • Rena Conti, PhD, Assistant Professor of Health Policy & Economics, University of Chicago • Ed Pezalla, MD, MPH, National Medical
Load more

Recommended publications
  • BIOWORLD TODAY Inquiry
    BIOWORLDTM TODAY THE DAILY BIOPHARMACEUTICAL NEWS SOURCE JUNE 30 , 2016 BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS VOLUME 27, NO. 126 LIPID JAM NOT OVER EASILY STOPPED FOR FUTILITY Waffle house? FDA Galena Biopharma implodes as PRESENT review fidgets endpoint, puts cancer vaccine Neuvax future in doubt outcome details; By Jennifer Boggs, Managing Editor Esperion grilled on holdup With the bulk of Galena Biopharma Inc.’s value riding on cancer vaccine Neuvax By Randy Osborne, Staff Writer (nelipepimut-S), the firm’s shares predictably plunged to a new 52-week low Wednesday as an independent data monitoring committee (IDMC) recommended the Analysts had plenty of questions but PRESENT phase III study in breast cancer be stopped for futility following a planned Esperion Therapeutics Inc. offered few interim analysis. But it’s the troubling language in the IDMC’s letter, suggesting the answers regarding the FDA’s stalling on placebo arm might actually have bested the treatment arm, that could signal the end oral, once-daily bempedoic acid (ETC- of the road for Neuvax. 1002) for lipid lowering, after the agency See Galena, page 3 See Esperion, page 4 CHINA DEALS AND M&A IN THE CLINIC Pfizer invests in Asia Merck strikes cancer SUPER ‘NOVA’ with $350M biotech vaccines deal with Tesaro shares blast plant in Hangzhou Moderna, delivering off as niraparib hits By Haky Moon, Staff Writer $200M up front PFS in ovarian cancer HONG KONG – China’s economy may By Michael Fitzhugh, Staff Writer By Marie Powers, News Editor be slowing down, but multinationals Findings from the phase III NOVA trial are positioning themselves to leverage Cancer vaccines tailored to fit tumor- specific profiles are at the heart of a new of niraparib in women with recurrent it as best they can while navigating a ovarian cancer blasted shares of still-complex regulatory environment.
    [Show full text]
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • Monday, April 22 Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Merck KLOX Technologies Immune Design Leading Biote
    As of 4/23/2013 Schedule subject to change Monday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room April 22 Merck KLOX Technologies Immune Design 1:00 PM Leading Biotech/Big Pharma Medical Devices Vaccines Eli Lilly NewSouth Innovations Syntiron 1:15 PM Leading Biotech/Big Pharma University/Academia Vaccines Amgen Radius Health BioCrea 1:30 PM Leading Biotech/Big Pharma Musculoskeletal Neurology/CNS Nat. Inst. of Neurological Dis. & Stroke Cytokinetics Xenon Pharmaceuticals 1:45 PM Neurology/CNS Musculoskeletal Neurology/CNS Curis OrgaNext Research BV Trigemina 2:00 PM Oncology Regenerative Medicine Neurology/CNS Verastem Flexion Therapeutics Neurocrine Biosciences 2:15 PM Oncology Musculoskeletal Hormone Therapy/CNS Michael J. Fox Foundation Antisense Pharma GmbH Versartis 2:30 PM Non-profit/Patient Advocacy Oncology Hormone Therapy Takeda Pharmaceutical Company TBD KODE Biotech 2:45 PM Leading Biotech/Big Pharma Drug Delivery Resverlogix Corp. Advaxis Q Chip 3:00 PM Cardiovascular Disease Oncology Drug Delivery Grünenthal GmbH Array BioPharma 3:15 PM Neurology/CNS Oncology/Drug Discovery Discovery Labs Mersana Therapeutics 3:30 PM Drug Delivery/Pulmonary Oncology Bayer HealthCare Igenica 3:45 PM Leading Biotech/Big Pharma Oncology Presentations are open to all Convention attendees and are located outside the main entrance of the BIO Business Forum As of 4/23/2013 - Schedule subject to change Tuesday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Chicago Blackhawks Room April 23 Pfizer 8:00 AM Leading Biotech/Big Pharma
    [Show full text]
  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/08/2015 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 21:25:58 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2015 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 65162 AMNEAL PHARMACEUTICALS LLC 00074 ABBOTT LABORATORIES 69238 AMNEAL PHARMACEUTICALS, LLC 68817 ABRAXIS BIOSCIENCE, LLC 53150 AMNEAL-AGILA, LLC 16729 ACCORD HEALTHCARE INCORPORATED 00548 AMPHASTAR PHARMACEUTICALS, INC. 42192 ACELLA PHARMACEUTICALS, LLC 66780 AMYLIN PHARMACEUTICALS, INC. 10144 ACORDA THERAPEUTICS, INC. 55724 ANACOR PHARMACEUTICALS 00472 ACTAVIS 10370 ANCHEN PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 62559 ANIP ACQUISITION COMPANY 45963 ACTAVIS INC. 54436 ANTARES PHARMA, INC. 46987 ACTAVIS KADIAN LLC 52609 APO-PHARMA USA, INC. 49687 ACTAVIS KADIAN LLC 60505 APOTEX CORP. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 63323 APP PHARMACEUTICALS, LLC. 67767 ACTAVIS SOUTH ATLANTIC 42865 APTALIS PHARMA US, INC 66215 ACTELION PHARMACEUTICALS U.S., INC. 58914 APTALIS PHARMA US, INC. 52244 ACTIENT PHARMACEUTICALS 13310 AR SCIENTIFIC, INC. 75989 ACTON PHARMACEUTICALS 08221 ARBOR PHARM IRELAND LIMITED 76431 AEGERION PHARMACEUTICALS, INC. 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 50102 AFAXYS, INC. 24338 ARBOR PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 59923 AREVA PHARMACEUTICALS 27241 AJANTA PHARMA LIMITED 76189 ARIAD PHARMACEUTICALS, INC. 17478 AKORN INC 24486 ARISTOS PHARMACEUTICALS, INC. 24090 AKRIMAX PHARMACEUTICALS LLC 67877 ASCEND LABORATORIES, L.L.C. 68220 ALAVEN PHARMACEUTICAL, LLC 76388 ASPEN GLOBAL INC. 00065 ALCON LABORATORIES, INC. 51248 ASTELLAS 00998 ALCON LABORATORIES, INC. 00469 ASTELLAS PHARMA US, INC. 25682 ALEXION PHARMACEUTICALS 00186 ASTRAZENECA LP 68611 ALIMERA SCIENCES, INC.
    [Show full text]
  • February 11-12, 2013 the Waldorf Astoria New York
    February 11-12, 2013 The Waldorf Astoria New York 15th ANNU AL EVENT Now in its fifteenth year, the BIO CEO & Investor Conference is the largest independent investor conference focused on leading publicly-traded biotech companies. The meeting provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. Reasons Top 10 to attend 1 Present your company story to an audience of targeted investors. 2 Hear the Washington perspective on the Affordable Care Act, debt ceiling, and other timely policy developments affecting the industry. 3 Evaluate fresh investment opportunities including compatible, complementary and competitive companies. 4 Learn about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. 5 Attend fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2013. 6 Gain access to BIO’s 1x1 Partnering System for scouting potential deal partners and optimizing your time at the event. 7 Access presentations from more than 140 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. 8 Get the pulse on the current and proposed investment trends in biotechnology. 9 Network with peers, investors and potential partners attending the conference. 10 It’s the first NYC biotech conference of the year, kicking off a week of key industry events that you don’t want to miss.
    [Show full text]
  • Galena Biopharma, Inc. (Exact Name of Registrant As Specified in Its Charter) ______
    ANNUAL REPORT 201 OUR MISSION GALENA BIOPHARMA DEVELOPS AND COMMERCIALIZES INNOVATIVE, TARGETED ONCOLOGY TREATMENTS THAT ADDRESS MAJOR UNMET MEDICAL NEEDS TO ADVANCE CANCER CARE. MANAGEMENT TEAM Mark J. Ahn, Ph.D., President & Chief Executive Officer Remy Bernarda, Vice President, Marketing & Communications Gavin Choy, Pharm.D., Senior Vice President, Clinical Operations & Cinical Science Ryan Dunlap, CPA, Vice President, Chief Financial Officer Brian Hamilton, M.D., Ph.D., Executive Vice President & Chief Medical Officer Robert Laliberte, MS, Vice President, Clinical Operations & Clinical Science Christopher Lento, Vice President, Sales & Commercial Operations Hana B. Moran, Ph.D., Senior Vice President, Regulatory & Compliance Patricia Murphy, Vice President, Regulatory Affairs & Compliance Mark W. Schwartz, Ph.D., Executive Vice President & Chief Operating Officer SCIENTIFIC ADVISORY BOARD COL George Peoples, M.D., F.A.C.S., Chief, Surgical Oncology, Brooke Army Medical Center; Director and Principal Investigator, Cancer Vaccine Development Program, San Antonio Military Medical Center Hope S. Rugo, M.D., Clinical Professor of Medicine, Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Care Center Robert Figlin, M.D., F.A.C.P., Dr. Figlin is a fellow of the American College of Physicians and the International Society for Biologic Therapy as well as a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Urological Association. Dr. Gabriel N. Hortobagyi, M.D., F.A.C.P., is a Professor of Medicine and Chairman of the Department of Breast Medical Oncology and holds the Nellie B. Connally Chair in Breast Cancer Research at the University of Texas MD Anderson Cancer Center (MDACC).
    [Show full text]
  • CDER – Redi: Focus on CGMP & FDA Inspections – Participant List
    FDA – CDER – RedI: Focus on CGMP & FDA Inspections – Participant List These participants granted permission to share their contact information Eileen Zhou Michael Channing A B M Mahfuz ul Alam Research Associate Group Chief - Positron Emission General Manager, Quality Operations Neuralstem Tomography Department ACI HealthCare Limited Germantown, MD, United States NIH Dhaka, Non-US, Bangladesh [email protected] Bethesda, MD, United States [email protected] [email protected] Abe Wong ABHIJEET GUJAR Adam Ebbinghouse CCO Chief Operating Officer QC Associate Gmpsigma SETHU KP Pharmaceutical Technology, Inc. Seattle, WA, United States Porvorim Goa, Non-US, India Bloomington, IN, United States [email protected] [email protected] [email protected] Adil Gatrad Adiseshu Modugula Aditiben Patel Director, Quality Systems RA Regulatory Specialist Actavis MSN USAMMDA Parsippany, NJ, United States Hyderabad, Non-US, India Frederick, MD, United States [email protected] [email protected] [email protected] Adriana de la Cruz ahsanul haque Aimee Gogarty Manager CSO Quality Coordinator Laboratorios Pisa SA de CV FDA Mallinckrodt Jalisco, Non-US, Mexico silver spring, MD, United States Port Allen, LA, United States [email protected] [email protected] [email protected] Aislyn Fronzak Ajay Deshmukh Ajay Khedkar QC Manager QA manager Regulatory Affair PL Developments Ingenus Pharmaceutical Umedica Laboratories Pvt Ltd Clinton, SC, United States Navi mumbai, Non-US, India Mumbai, Non-US, India [email protected]
    [Show full text]
  • Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
    Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential The Life Sciences Report www.TheLifeSciencesReport.com 05/02/2013 In January 2013, The Life Sciences Report debuted its biotech COMPANIES MENTIONED Watchlist, which outlined ideas for investors keyed to catalysts in Amarin Corp. the drug development process that typically move biotechnology Astellas Pharma Inc. stocks. All stocks are affected by catalysts, but nowhere do they Bayer provide more leverage (or deleverage) than in biotech. We Cardinal Health Inc. predicted the new year would present legitimate prospects for Celsion Corp. portfolio growth. So far, that has been the case. Although the party has given Galena Biopharma Inc. way to some fatigue, the punch bowl is still on the table and the biotech Hyperion Therapeutics upswing continues. Inc. Medivation Inc. Source: George S. Mack of The Life Sciences Report Navidea Biopharmaceuticals Inc. Back in January, our friends and collaborators at San Diego-based Sagient Novartis AG Research, publishers of the BioMedTracker, offered important information about Onyx Pharmaceuticals market-moving data and events that can make or break smaller companies. In Inc. addition, a group of key biotech analysts weighed in on their best ideas—17 stocks Peregrine Pharmaceuticals Inc. in all. It was the perfect storm of individual ideas combined with a biotech wind from Pfizer Inc. 2012 still billowing the sails. As of April 22, the NASDAQ Biotechnology (NBI) Pharmacyclics Inc. index is up 26.6%. Have the biotech companies that made inaugural Biotech Prana Biotechnology Ltd. Watchlist—and their stocks—met the targets identified in the first quarter of 2013? Sangamo BioSciences Are there new catalysts? Check out the progress in the updated April 2013 Biotech Inc.
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • The Weekly Shot Biotech Issue a Weekly Summary of Healthcare Industry Valuation and Near-Term Catalysts June 17, 2010
    Small Cap The Weekly Shot Biotech Issue June 17, 2010 A weekly summary of healthcare industry valuation and near-term catalysts The Weekly Shot: Overview and Comment - Small Cap Biotechnology Next week's sector highlights include LGND’s Thursday analyst event at the Eventi - Pharmaceuticals and Large Cap Biotech Hotel in NYC. The company on 6/15 announced updated 2010 revenue guidance of approx $25M, op ex of approx $30M, and expects to finish the year with $30M - Generics and Specialty Pharmaceuticals in cash (vs approx $43M as of 1Q10). Management will likely focus on partner GSK’s progress with add’l trials of Promacta (for ITP), which could potentially expand the drug’s label to Hep C, AML, and MDS (LGND receives <10% royalty from GSK). Investors should focus on pipeline plans following LGND’s opportunistic 2008/09 M&A activity. Key pipeline programs include LGD-4033 (ph.I, SARM candidate from PCOP) and RG7348, partnered with Roche (ph.I, Hep C candidate from MBRX). We do not expect major data announcements at the event. FDA’s Pediatric Drugs Advisory Committee will meet Monday to discuss pediatric safety reviews of multiple approved drugs, including Kogenate, Casodex, Apidra, NovoLog, Arimidex, Desmopressin, Prevacid, Nexium, Aciphex, Priolex, OraVerse, Zemuron, and Suprane . While important from a public safety perspective, we do not anticipate regulatory activity to be announced. Brian Lian, Ph.D. Small caps biotechs rebounded mid-week as elevated volatility continued across 212.500.6646 [email protected] the broader market. Investors are struggling to balance economic data supporting a modest recovery against concerns on EU debt loads, financial reform legislation, and aggressive govt rhetoric on BP’s oil spill.
    [Show full text]
  • CURRICULUM VITAE MARK DAVID SANCHEZ, MD, FACOG 2454 Mcmullen Booth Rd., Suite 601 Phone: (727) 796­7705
    CURRICULUM VITAE MARK DAVID SANCHEZ, MD, FACOG 2454 McMullen Booth Rd., Suite 601 Phone: (727) 796­7705 CURRENT POSITIONS Reproductive Endocrinologist IVF Medical Director Florida Fertility Institute Clearwater, Florida Associate Medical Director and Investigator Women's Medical Research Group, LLC Clearwater, Florida Associate Medical Director and Investigator Florida Clinical Research Group Clearwater, Florida Department Chair Obstetrics and Gynecology Bayfront Medical Center St. Petersburg, Florida BIRTH DATE and PLACE March 25, 1969, Indianapolis, IN EDUCATION and TRAINING 1999­2002 Fellowship in Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology University of South Florida Tampa, Florida 1995­1999 Obstetrics and Gynecology Residency Department of Obstetrics and Gynecology Bayfront Medical Center St. Petersburg, Florida 1991­1995 Doctor of Medicine University of Florida College of Medicine Gainesville, Florida 1989­1991 Bachelor of Science Major: Biology Minor: History University of South Florida Tampa, Florida WORK EXPERIENCE 2002­2014 Reproductive Endocrinologist IVF Medical Director Florida Fertility Institute Clearwater, Florida 2003­2014 Associate Medical Director and Investigator Women's Medical Research Group, LLC Clearwater, Florida 2003­2014 Associate Medical Director and Investigator Florida Clinical Research Group Clearwater, Florida LICENSES, CERTIFICATIONS, AND EXAMINATIONS 1996 Florida Medical License (Active) 2005 Board Certified Reproductive Endocrinology and Infertility 2004 Board Certified
    [Show full text]
  • FIDELITY SELECT PORTFOLIOS Form N-Q Filed 2017-01-27
    SECURITIES AND EXCHANGE COMMISSION FORM N-Q Quarterly schedule of portfolio holdings of registered management investment company filed on Form N-Q Filing Date: 2017-01-27 | Period of Report: 2016-11-30 SEC Accession No. 0001379491-17-000373 (HTML Version on secdatabase.com) FILER FIDELITY SELECT PORTFOLIOS Mailing Address Business Address 245 SUMMER STREET 245 SUMMER STREET CIK:320351| IRS No.: 000000000 | State of Incorp.:MA | Fiscal Year End: 0228 BOSTON MA 02210 BOSTON MA 02210 Type: N-Q | Act: 40 | File No.: 811-03114 | Film No.: 17551660 617-563-7000 Copyright © 2017 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM N-Q QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED MANAGEMENT INVESTMENT COMPANY Investment Company Act file number 811-3114 Fidelity Select Portfolios (Exact name of registrant as specified in charter) 245 Summer St., Boston, Massachusetts 02210 (Address of principal executive offices) (Zip code) Marc Bryant, Secretary 245 Summer St. Boston, Massachusetts 02210 (Name and address of agent for service) Registrant's telephone number, including area code: 617-563-7000 Date of fiscal year end: February 28 Date of reporting period: November 30, 2016 Item 1. Schedule of Investments Quarterly Holdings Report for Fidelity® Select Portfolios® Semiconductors Portfolio (formerly Electronics Portfolio) November 30, 2016 ELE-QTLY-0117 1.810682.112 Copyright © 2013 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Investments November 30, 2016 (Unaudited) Showing Percentage of Net Assets Common Stocks - 95.3% Shares Value Biotechnology - 0.0% Biotechnology - 0.0% Arrowhead Pharmaceuticals, Inc.
    [Show full text]